Encysive Pharmaceuticals

Encysive Pharmaceuticals, Inc. is a pioneering biopharmaceutical company focused on combatting vascular and inflammatory diseases through the development and commercialization of synthetic and small molecule compounds. The company's dedication to research and development is evident in its range of products, including Argatroban for treating heparin-induced thrombocytopenia, and Thelin (sitaxsentan sodium), designed to address pulmonary arterial hypertension, congestive heart failure, and essential hypertension. The clinical development pipeline features promising candidates such as TBC3711, TBC4746, ENC8003, and bimosiamose, targeting various receptors and conditions. Established in 1989 as Texas Biotechnology Corporation and rebranded to Encysive Pharmaceuticals, Inc. in 2003, the company has solidified research collaborations and licensing agreements with industry giants like GlaxoSmithKline plc, Mitsubishi Pharma Corporation, Schering-Plough, Ltd., Schering Corporation, and Revotar Biopharmaceuticals, AG. Notably, Encysive Pharmaceuticals received a significant $13.95MPrivate Equity Round investment on 20 August 2007, led by Enable Capital Management and Hudson Capital Group. Based in Houston, Texas, Encysive Pharmaceuticals, Inc. operated as a subsidiary of Pfizer Inc. as of June 10, 2008. The company's commitment to addressing critical medical needs and strategic collaborations positions it as a contender in the biotechnology and pharmaceutical industries.